Background: The Pfizer-BioNTech® BNT162b2 vaccine, provides 95% effectiveness from the second dose onwards. The reported rate of anaphylaxis to COVID-19 vaccines is 4.7 cases/million doses administered. Case report: 30-year-old female, health professional, history of allergic rhinitis, asthma, reaction to eye cosmetics and adhesive tape: erythema, edema, and local pruritus. Immediately after application of the first dose of Pfizer-BioNTech vaccine, she presented grade III anaphylaxis. The patient was stratified, phenotyped and skin tests with PEG 3350 were positive. A recommendation was issued not to reapply vaccine containing polyethylene glycol and alternatives were offered. Conclusion: An adequate risk stratification should be performed before applying mRNA-based COVID-19 vaccines for the first time in at-risk groups. In case of anaphylaxis at the first dose, phenotyping and further study with PEG skin tests should be performed and vaccination alternatives should be offered.
CITATION STYLE
Estrada-García, C. D., Macías-Robles, A. P., Cortés-Grimaldo, R. M., Carvajal-Alonso, H. L., Barreto-Alcalá, M., Ramírez-Nepomuceno, A., … Campos-Téllez, H. H. (2022). Allergy to Pfizer-BioNTech® vaccine demonstrated by skin testing. Revista Alergia Mexico, 69(2), 89–92. https://doi.org/10.29262/ram.v69i2.1088
Mendeley helps you to discover research relevant for your work.